Inclusion Criteria:

- Histologically- Or Cytologically- Confirmed Metastatic Or Locally Advanced Solid
Tumors That Has Failed To Respond To Standard Therapy, Or For Which Adequate Standard
Therapy Dose Not Exist

- Tumors Associated With Igf-1r Expression In The Literature (E.G. Prostate,
Pancreatic, Colon, Lung And Breast)

- Ecog Performance Status 0 or 1

- Adequate Organ Function

Exclusion Criteria:

- Patient Who Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks
(6 Weeks For Nitrosoureas Or Mitomycin C) Prior To Registration

- Patients Is Concurrently Using Growth Hormone (Gh), Or Growth Hormone Inhibitor

- Any Active CNS Metastases And/Or Carcinomatous Meningitis

- Any Primary Central Nervous System Tumor - Any Symptomatic Ascites Or Plural
Effusion

- A History Or Current Evidence Of Any Clinically Significant Disease That Might
Confound The Results Of The Study, Complicate The Interpretation Of The Study
Results, Interfere With The Patient'S Participation, Or Pose An Additional Risk To
The Patient

- Pregnant Or Breast-Feeding